The Protective Function of Galectin-9 in Liver Ischemia and Reperfusion Injury in Mice

Hirofumi Hirao,1,2 Yoichiro Uchida,1,2 Kentaro Kadono,1,2 Hirokazu Tanaka,1 Toshiro Niki,5,6 Akira Yamauchi,3 Koichiro Hata,1 Takeshi Watanabe,4 Hiroaki Terajima,2 and Shinji Uemoto1

1Department of Surgery, Division of Hepato-Pancreato-Biliary Surgery and Transplantation, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Departments of 2Gastroenterological Surgery and Oncology, 3Breast Surgery, 4Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan; 5Department of Immunology and Immunopathology, Faculty of Medicine, Kagawa University, Kagawa, Japan; and 6GalPharma Co., Ltd., Kagawa, Japan

Galectin-9 (Gal-9) has gained attention as a multifaceted player in adaptive and innate immunity. To elucidate the role of Gal-9, we used a mouse model of partial liver ischemia/reperfusion injury (IRI) with wild type (WT) and Gal-9 knockout (KO) mice as well as a recombinant galectin-9 (reGal-9) protein. We found that the expression of Gal-9 was enhanced endogenously in the liver especially by hepatocytes and Kupffer cells during warm IRI for a mouse liver, which causes massive destruction of liver tissue. Gal-9 was released into the extracellular space in the liver and the highest levels in the plasma at 1 hour after reperfusion. The present study elucidates a novel role of Gal-9 signaling in mouse liver IRI, by using Gal-9-deficient mice and a stable form of reGal-9 protein. In the circumstance of Gal-9 absence, liver damage due to ischemia/reperfusion (IR) exacerbated the severity as compared with WT. On the other hand, exogenously administered reGal-9 significantly ameliorated hepatocellular damage. It decreased the local infiltration of the inflammatory cells such as T cells, neutrophils, and macrophages, and it reduced the expression of proinflammatory cytokines/chemokines; then, it strongly suppressed the apoptosis of the liver cells. Interestingly, severe liver damage due to IR in Gal-9 KO mice was improved by the administration of reGal-9. In conclusion, Gal-9 engagement ameliorated local inflammation and liver damage induced by IR, and the present study suggests a significant role of Gal-9 in the maintenance of hepatic homeostasis. In conclusion, targeting Gal-9 represents a novel approach to protect from inflammation such as liver IRI. Exogenous Gal-9 treatment will be a new therapeutic strategy against innate immunity-dominated liver tissue damage. Liver Transpl 21:969-981, 2015. © 2015 AASLD.

Received February 10, 2015; accepted April 7, 2015.

Galectins are involved in various processes including embryonic development, tumor biology, and regulation of the immune system,1 and they are evolutionarily conserved glycan-binding proteins with diverse roles in innate and adaptive immune responses.2 At least 15 galectins have been identified in mammals.3 Notably,
galectin-9 (Gal-9), a member of the galectin family, is ubiquitously expressed in a variety of tissues and is particularly abundant in the liver. Gal-9 was first identified as an apoptosis-inducing factor for thymocytes and an eosinophil-activating factor. Recently, several articles have reported that Gal-9 treatment ameliorated inflammation in mouse experimental models of autoimmune encephalomyelitis, arthritis, myocarditis, polymicrobial sepsis, diabetes, and hepatitis.

Ischemia/reperfusion injury (IRI) still remains an important problem in clinical transplantation. IRI in the liver causes approximately 10% of early graft failure, can lead to a higher incidence of acute and chronic rejection, and contributes to the acute shortage of donor organs available for transplantation. The mechanisms underlying liver IRI are complex but are known to involve the activation of T cells and macrophages including Kupffer cells and neutrophils, leading to the formation of reactive oxygen species, secretion of proinflammatory cytokines/chemokines, complement activation, and vascular cell adhesion molecule activation. The acute inflammation response during liver reperfusion consists of 2 phases: acute and subacute response. In the acute phase at 3 to 6 hours after reperfusion, hepatocellular injury associates with T lymphocyte and Kupffer cell activation. In the subacute phase at 18 to 24 hours, massive neutrophil accumulation takes place. Especially, at 1 hour after reperfusion, CD4 positive T lymphocytes are the key regulator in initiating ischemia/reperfusion (IR)-induced liver inflammation. T cell–Kupffer cell interaction constitutes a key event in liver IRI; however, there is not enough data to prove this mechanism.

MOleculars of the T cell immunoglobulin mucin (TIM) family represent relatively newly described immune regulators. Recent experiments have revealed that Gal-9 has been identified as a ligand for TIM-3. Binding of Gal-9 to TIM-3 causes an inhibitory signal that results in the induction of apoptosis of T helper (Th) 1 cells and down-regulated Th1-type immunity. The activation of the TIM-3/Gal-9 pathway negatively regulates activated CD4+ and CD8+ alloreactive T cells and results in the prolonged survival of allogeneic skin grafts. It has been reported that the TIM-1/TIM-4 or TIM-3/Gal-9 pathway represents one of the key mechanisms underlying T cell–Kupffer cell crosstalk in the pathophysiology of liver IRI.

This study was focused on examining the putative role of Gal-9 in the pathophysiology of a mouse liver model for warm IRI. Our results demonstrate that Gal-9 engagement ameliorated local inflammation and liver damage due to IRI, suggesting the importance of Gal-9 signaling in the maintenance of hepatic homeostasis, expansion of the organ donor pool, and improvement of the overall success of liver transplantation.

MATERIALS AND METHODS

Animals

Male C57BL/6 mice (9 to 12 weeks, 25 to 30 g weight) were purchased from CLEA Japan, Inc. (Osaka, Japan). Gal-9 knockout (KO; Gal-9/-) mice were kindly provided by GalPharma (Takamatsu, Japan). All animals were maintained under specific pathogen-free conditions and received humane care according to the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication, 8th edition, revised, 2011). All experimental protocols were approved by the Animal Research Committee of Kyoto University.

Liver IRI Model

We used an established mouse model of partial warm hepatic IRI. An atraumatic clip was used to interrupt the artery/portal venous blood supply to the left/middle liver lobes. After 90 minutes of ischemia, the clamp was removed, initiating reperfusion (Supporting Fig. 1A). To investigate the function of Gal-9, mice were given an intravenous injection of a stable form of recombinant galectin-9 (reGal-9) protein (60 μg/bdy), provided by GalPharma (Takamatsu, Japan) at 30 minutes before the ischemia insult, and then were killed 6 and 24 hours after reperfusion. Control mice were pretreated with phosphate-buffered saline (PBS). Sham-operated mice underwent the same procedure but without vascular occlusion.

Hepatocellular Function

Serum alanine aminotransferase (sALT) levels in peripheral blood, an indicator of hepatocellular injury, were measured by a standard spectrophotometric method with an automated clinical analyzer (JCA-BM9030; JEOL, Ltd., Tokyo, Japan).

Histology

Liver paraffin sections (4-μm thick) were stained with hematoxylin-eosin (H & E). The severity of liver IRI (necrosis, sinusoidal congestion, and centrilobular ballooning) was blindly graded with a modified Suzuki's criteria on a scale from 0 to 4.

Immunohistochemistry

Rat monoclonal antibodies (mAbs) against mouse Gal-9 (108A2; Biologend, San Diego, CA), CD3 (17A2; TONBO biosciences, Irvine, CA), CD68 (FA-11; AbD Serotec, Kidlington, UK), or lymphocyte antigen 6 complex locus G (Ly6-G; RB6-8C5; Tonbo Biosciences, Irvine, CA) were applied on liver paraffin-embedded sections. Then, biotinylated rabbit anti-rat immunoglobulin G (IgG) and goat anti-rabbit IgG were applied. After incubation, immunoperoxidase (VECTASTAIN Elite ABC Kit, Vector Labs, Burlingame, CA) was applied to the sections. Positive cells were counted blindly at 10 high-power field (HPF)/section (×400). Negative controls were prepared by incubation with normal rat IgG or rabbit IgG (sc-2026, 2027; Santa Cruz Biotechnology, Santa Cruz, CA) instead of the first antibody (Ab).
Enzyme-Linked Immunosorbent Assay for Gal-9
Plasma Gal-9 level was quantified by enzyme-linked immunosorbent assay as reported previously. Anti-mouse Gal-9 mAb (GalPharma), following the addition of anti-rabbit IgG-biotin (Southern Biotech, Birmingham, AL), was used for detection. Samples were quantified by using streptavidin (SA)-HRP (Thermo Scientific, Rockford, IL) and tetramethylbenzidine (Biologend) and were measured by a spectrophotometer.

Quantitative Reverse-Transcription Polymerase Chain Reaction (PCR)
Total RNA was extracted from the liver tissue using the RNeasy Kit (Qiagen, Venlo, the Netherlands) and complementary DNA was prepared by Omniscript RT kit (Qiagen). Quantitative PCR was performed using the StepOnePlus Real-Time PCR System (Life Technologies, Tokyo, Japan). Primers used to amplify specific gene fragments have been listed (Supporting Table 1).
Target gene expression was calculated by the ratio to the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

**Western Blot Assay**

Ab recognizing Gal-9 (Biolegend), Ab to toll-like receptor 4 (TLR4; Santa Cruz Biotechnology), Ab to cleaved caspase-3 (Asp175; CST, Danvers, MA), and β-actin (PM053; MBL, Nagoya, Japan) were used for detection of each molecule, respectively. The intensity of the bands was quantified with imaging analysis software (CS Analyzer, Atto Corporation, Tokyo, Japan).

**Apoptosis Assay**

Apoptosis in 4-μm liver paraffin sections was detected by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) method using the In Situ Apoptosis Detection Kit (Takara Bio, Shiga, Japan) according to the manufacturer’s protocol. Negative control was prepared by the omission of terminal deoxynucleotidyl transferase. Positive controls were generated by treatment with deoxyribonuclease. TUNEL-positive cells were counted in 10 HPF/section under light microscopy.

**Statistical Analysis**

All data are expressed as means ± standard error of mean (SEM). Differences between experimental groups were analyzed using 1-way analysis of variance or Student t test for unpaired data. All differences were considered statistically significant at the P value of <0.05.

**RESULTS**

**Gal-9 Protein Expression Was Up-Regulated in the Liver and Blood Upon IR Insult**

The concentration of Gal-9 in blood and the expression of Gal-9 in liver tissues of mice that underwent 90 minutes of warm ischemia followed by 168 hours of reperfusion were examined. The concentration of Gal-9 in plasma showed a high level 1 hour after reperfusion, despite its low level just before reperfusion. Then, it gradually decreased with the duration up to 168 hours after reperfusion (Fig. 1A). On the contrary, as shown in immunohistochemistry (Fig. 1B) and western blot analysis (Fig. 1D), the expression of Gal-9 in the liver had already started during ischemia insult before reperfusion, which was clearly detected in nonparenchymal cells as well as in hepatocytes. Because the feature of Gal-9-positive cells in the nonparenchymal region was consistent with F4/80-positive cells (unpublished data), it is plausible that the Gal-9-positive cells in the nonparenchymal area are thought to be the activated resident Kupffer cells in the liver. One hour after the start of reperfusion, the Gal-9 expression in the liver increased more clearly in the area of the nucleus and cell cytoplasm of hepatocytes (Fig. 1C). Notably, the Gal-9 expression in the liver and the number of Gal-9-positive cells bottomed at 6 hours after reperfusion, which indicated the maximum liver injury due to IR. However, the Gal-9-positive cells and the amounts of Gal-9 in the liver then increased continuously up to 168 hours after reperfusion (Fig. 1C, D). These results indicated a significant involvement of Gal-9 in mouse liver IRI.

**Absence of Gal-9 Exacerbated Liver IRI**

Hepatocellular damages in warm IRI were analyzed by using wild type (WT) mice and Gal-9-deficient mice. The damage due to IR was profoundly exacerbated in Gal-9-/- mice, compared with WT. As shown in Fig. 2A, the sALT levels in Gal-9-/- mice were significantly increased both 6 and 24 hours after reperfusion. These data correlated well with Suzuki’s histological criteria of the hepatocellular damages, composed of necrosis, sinusoidal congestion, and centrilobular ballooning (Fig. 2B). The livers in Gal-9-/- mice showed severe liver tissue damages, which were comparable with or higher than those in wild mice. The results indicated that the absence of Gal-9 exacerbated liver damages caused by IR injury.

**ReGal-9 Pretreatment Ameliorated Liver IRI**

To elucidate the function of Gal-9 during liver IR, we applied reGal-9 in our mouse IRI model.26 ReGal-9 was intravenously administered into wild or Gal-9-/- mice 30 minutes before the ischemia insult (Supporting Fig. 1A). As shown in Fig. 2A, the sALT levels in IR-treated WT mice which had been pretreated with reGal-9 were remarkably decreased both 6 and 24 hours after reperfusion, as compared to IR-injured wild mice without Gal-9 administration. Moreover, the sALT levels in IR-injured Gal-9-/- mice pretreated with reGal-9 were also significantly decreased. Notably, although the alanine aminotransferase level in the Gal-9-/- mice pretreated with Gal-9 was still high at 6 hours after reperfusion, it was dramatically reduced 24 hours after reperfusion and became at an almost equal level to the reGal-9 pretreated wild mice. Thus, the pretreatment with reGal-9 ameliorated IR-induced hepatocellular damages in wild mice as well as Gal-9-deficient mice. Moreover, even when reGal-9 was intravenously administered after a 90-minute ischemia insult (Supporting Fig. 1A), the sALT levels were significantly improved (Supporting Fig. 1B). In histological findings as shown in Fig. 2B, the livers in PBS-pretreated WT or Gal-9-/- mice revealed severe lobular edema, congestion, ballooning, and hepatocellular necrosis. In contrast, the exacerbated hepatocellular damages in wild or Gal-9-/- mice were improved both 6 and 24 hours after reperfusion by the pretreatment with reGal-9. Livers in reGal-9-pretreated WT or Gal-9-/- mice showed good preservation of architecture.
and histological detail. Indeed, the Suzuki's score was significantly improved both 6 and 24 hours after reperfusion in the reGal-9–pretreated WT and Gal-9−/− mice (Suzuki score; Fig. 2B). Thus, the protective effect of reGal-9 was confirmed in the mouse IR injury. The Gal-9 expression in the liver tissues clearly increased at 6 hours after reperfusion by the pretreatment with reGal-9 (Fig. 3). Although the Gal-9 expression was markedly reduced at 6 hours in the IR-induced wild mice, pretreatment with reGal-9 profoundly enabled enhanced Gal-9 expression in the IR-induced wild mice 6 hours after reperfusion. Surprisingly, such enhanced production of Gal-9 was remarkable even 24 hours after the start of reperfusion during IR insult (Fig. 3B). These data indicated that the changes in Gal-9 protein level in the livers of IR-injured mice are strictly related to the damages of the liver and that exogenous administration of reGal-9 could efficiently protect liver from the damages caused by IR.

Figure 2. Liver damage induced by IRI in wild mice or Gal-9 deficient mice with or without reGal-9 pretreatment. (A) Hepatocellular damage measured by sALT levels at 6 and 24 hours. (B) Top: representative liver histology (H & E staining; magnification ×100) of liver lobes harvested 6 and 24 hours after reperfusion. Bottom: quantitation of Suzuki's histological criteria of the hepatocellular damage. Means and SEM are shown (∗P < 0.05; **P < 0.01; ***P < 0.001; n = 6–8/group).
Figure 3. Exogenous reGal-9 administration enhanced Gal-9 expression on liver tissue. Actual Gal-9 expression was accessed (top) by immunohistochemistry (magnification ×100 and ×400) and (bottom) by western blot analysis. Means and SEM are shown (**P < 0.01; ***P < 0.001; n = 3/group).
Figure 4. Immunohistochemical staining for CD3-, CD68-, and Ly6-G–expressing cells in IRI livers. (A) Top: representative liver sections stained by CD3 (dark brown spots, as shown by circle). Bottom: quantitation of hepatic CD3 accumulation. (B) Top: representative liver sections stained by CD68 (dark brown spots). Bottom: quantitation of hepatic CD68 accumulation. (C) Top: representative liver sections stained by Ly6-G (dark brown spots; magnification ×400). Bottom: quantitation of hepatic Ly6-G accumulation. Means and SEM are shown (*P < 0.05; ***P < 0.001; n = 3/group).
Depletion of Gal-9 Increased T Cell, Macrophage, and Neutrophil Infiltration, Whereas ReGal-9 Pretreatment Suppressed the Infiltration

Although relatively small but significant numbers of CD3-positive T cells could be found in IR-injured wild mice, the numbers of T cells further decreased in the mice pretreated with reGal-9 at 6 hours after reperfusion (Fig. 4A). On the other hand, the numbers of T cells in Gal-9−/− mice increased as compared to the wild mice. As shown in Fig. 4B, reGal-9 pretreatment to the IR-injured wild mice lowered CD68 positive macrophage infiltration into the liver as compared with wild mice without reGal-9 pretreatment. In the IR-injured Gal-9−/− mice, the numbers of the CD68 positive macrophages were significantly increased at 6 hours after reperfusion. Numbers of Ly6-G positive cells, which are activated neutrophils, were significantly decreased in the livers of wild mice pretreated with reGal-9, especially at 24 hours after the reperfusion, as compared to mice without the reGal-9 pretreatment. On the contrary, the infiltration of neutrophils into the livers of Gal-9−/− mice increased 6 hours after reperfusion (Fig. 4C). Hence, Gal-9 suppressed the liver infiltration of inflammatory cells such as T cells, macrophages, and neutrophils and played a role in the inhibition of liver damage during IR.

Gal-9 Pretreatment Suppressed Proinflammatory Cytokines and Chemokines

We then examined the effects of a Gal-9 deficiency and the reGal-9 pretreatment on the expression of proinflammatory cytokines and chemokines, which have been reported to be important in the mechanism of liver IRI. Cytokines (tumor necrosis factor α [TNF-α], interleukin [IL]-6, IL-1β, and interferon [IFN]-γ) and chemokine ligand (CXCL; CXCL1 and CXCL2, which are chemotactic for macrophages) were measured during liver IRI by quantitative reverse-transcription PCR (Fig. 5). Six hours after reperfusion, reGal-9 pretreatment of the wild mice profoundly decreased the expression of TNF-α, IL-6, IL-1β, and IFN-γ. In addition, in Gal-9−/− mice, the expression of these cytokines was clearly increased compared to those of wild mice. The expression of CXCL1 and CXCL2 at 6 hours was significantly reduced in wild mice pretreated with reGal-9. The expression of CXCL1 in Gal-9−/− mice was significantly increased at 24 hours, and the expression of CXCL2 in Gal-9−/− mice was also increased significantly at 6 and 24 hours.

Gal-9 Pretreatment Suppressed IR-Induced Apoptosis of Hepatocytes

We examined how Gal-9 deficiency and treatment with reGal-9 affect the apoptosis of liver cells induced
by IRI (Fig. 6A). The number of cells in apoptosis (TUNEL-positive cells/field) induced by IR in wild mice significantly decreased in cases that were pretreated with reGal-9. In contrast, TUNEL-positive cells increased in Gal-9−/− mice compared with WT. In addition, pretreatment with reGal-9 inhibited the expression of cleaved caspase-3 at 24 hours after reperfusion (Fig. 6B). On the contrary, the expression of a cleaved caspase-3 level in the liver significantly increased in Gal-9−/− mice at both 6 and 24 hours after reperfusion. These data clearly demonstrate that Gal-9 plays a crucial role in the protection of liver damage induced by IR and in the maintenance of liver homeostasis.

**Gal-9 Suppressed Expression of TLR4 in Liver IRI**

Finally, the expression of TLR4, which has been reported to be critical in the pathogenesis of liver IRI, was measured by a western blot analysis (Supporting Fig. 2). Administration of reGal-9 suppressed the expression of TLR4 in the liver of the IR-injured wild mice both 6 and 24 hours after reperfusion. On the contrary, the expression level of TLR4 in the liver in the IR-injured Gal-9−/− mice significantly increased both 6 and 24 hours after reperfusion as compared with wild mice. Thus, reGal-9 suppressed TLR4 up-regulation induced by IRI. The data suggest that...
Gal-9 plays a crucial role in reducing the inflammation caused by IR through the down-regulation of TLR4 expression.

**DISCUSSION**

The present study provides clear evidence that Gal-9 has a crucial role as an endogenous protective factor in the pathogenesis of warm IRI in a mouse liver. First, Gal-9 expression in the liver rapidly increased at the early stage of liver IRI and continued during the course. Second, absence of Gal-9 exacerbated profoundly the IR-induced hepatocellular damage. On the contrary, administration of reGal-9 significantly improved liver damage because of IR in the wild as well as in the Gal-9−/− mice.

The most interesting data in this study are that the expression of endogenous Gal-9 was rapidly enhanced in the liver right after the onset of the liver IR insult, and this fast and furious expression started from an early time during IR, especially at the ischemic stage that is just before reperfusion. The expression reached to the peak at a very early time of the reperfusion stage, and it bottomed at 6 hours after reperfusion when the liver suffered severe damage as shown in Fig. 1D. Moreover, even 168 hours after the onset of reperfusion, hepatocytes still keep producing endogenous Gal-9 protein (Fig. 1C). Gal-9 concentration in plasma was the highest 1 hour after the start of reperfusion, and the concentration gradually reduced over time (Fig. 1A). These data imply that Gal-9 may recover homeostasis of the liver tissue.
through a rapid protective reaction against the damage caused by reperfusion. Previous reports revealed that Gal-9 production was induced and elevated from monocytes and macrophages by IFN-γ in the case of hepatitis C infection. Unlike the case of chronic liver damage by a virus, in the acute injury instance such as liver IRI, hepatocytes, and nonparenchymal cells such as Kupffer cells appeared to directly produce endogenous Gal-9 independently of the presence of IFN-γ.

Thus, the question arises as to how Gal-9 affects IR-caused liver damage. The function of endogenous Gal-9 was examined by using Gal-9 KO mice. As shown in Fig. 2, liver cell damage was exacerbated in both sALT level and in the histological finding as compared with those of WT mice. The absence of Gal-9 significantly increased the production of proinflammatory cytokines (TNF-α, IL-6, IFN-γ, and IL-1β) and chemokines (CXCL1 and CXCL2) in the liver upon IR. These cytokine/chemokine mediators are known to influence T cell/macrophage/neutrophil trafficking patterns in liver tissue. TNF-α triggers neutrophil-attracting CXC chemokines to express adhesion molecules on vascular endothelial cells. Neutrophil adhesion to endothelial cells leads to their transmigration into the liver parenchyma. Especially, neutrophil-derived neutrophil elastase induces inflammatory chemokines (CXCL1, CXCL2) and accelerates IR-mediated damage via the feedback mechanism with recruited neutrophils, which results in the direct injury to the membrane components. The data in the present study strongly support the critical "protective" role of Gal-9 against liver IRI by suppressing these vicious circles. Notably, the expression of Gal-9 has increased at an early stage of reperfusion before an increase in sALT as shown in Figs. 1 and 2. The rise of Gal-9 may provide an early warning signal; in other words, Gal-9 may play a crucial role as an alarmin in the case of liver IRI.

One of the key events after reperfusion is apoptosis of hepatocytes. In the setting of liver IRI related to Gal-9, activated caspase-3 also plays a key role in the final stages of the apoptotic cascade. As shown in Fig. 6, the liver tissues in the absence of Gal-9 showed an increased frequency of TUNEL cells, accompanied by an increased cleaved caspase-3 expression. This phenomenon was strongly suppressed by the administration of reGal-9. Gal-9 has been well known for induction of apoptosis in IFN-γ and IL-17 producing T cells and amelioration of autoimmunity in murine models. Gal-9 is a strong modulator of T cell immunity through its apoptotic effects on Tp1 and Tp17 cells in case of autoimmunity. Therefore, Gal-9 down-regulates the production of IFN-γ and other proinflammatory cytokines through induction of apoptosis in Tp1 cells, which is consistent with our present finding of decreased IFN-γ induction and T cell infiltration in the liver after reGal-9 administration.

It has been reported that Gal-9 is a ligand of TIM-3 that is expressed on Tp1 and Tp17 cells and that Gal-9 signaling induced the death of these cells, resulting in the suppression of Tp1- and Tp17-related cytokine production in vivo and in vitro. In addition, TIM-3/Gal-9 signaling may exert a "protective" function by depressing IFN-γ production in liver IRI settings, and anti-Gal-9 Ab treatment in vivo slightly exacerbated liver damage due to IR. The exogenous administration of reGal-9 administration may further facilitate the apoptosis of Tp1 cells through the activation of the Gal-9/TIM-3 pathway in Tp1 cells. A recent study shows that harnessing TIM-3/Gal-9 signaling at the T cell–hepatocyte interface facilitates homeostasis in IR-stressed orthotopic liver transplants. Our data strongly suggest that the interaction of Gal-9 with TIM-3 in the underlying mechanism will be essential in the regulation of liver IRI.

TLR4 has been reported to be involved in the initiation of IRI, as evidenced by the full protection of TLR4-deficient livers. The parenchymal hepatocyte is an active participant in the sterile inflammatory response after IR through TLR4-mediated activation of...
proinflammatory signaling. Administration of reGal-9 strongly down-regulated TLR4 expression and vice versa the Gal-9 deficiency induced up-regulation of TLR4 expression during IR injury (Supporting Fig. 2).

Figure 7 depicts the mechanisms underlying the liver IR injury on the basis of the present study and other previous reports. Thus, it will be plausible that IR insult induces the production of Gal-9 in the liver, which works as a protective function against tissue damage. However, the function and amounts of endogenous Gal-9 are not enough to recover the damages or maintain homeostasis of the liver environment caused by an IR insult; besides, endogenous Gal-9 is highly susceptible to proteolysis in the biological process. In order to overcome the problem, we used reGal-9, which is composed of tandem-repeat-type and is a highly stable galectin. The present study indicates that the administration of stable reGal-9 should be useful for inadequate amounts of endogenous Gal-9 and that it possesses a therapeutic potential for the prevention or treatment of IRI in the liver.

In conclusion, our data indicate an essential role of Gal-9 in the pathophysiology of liver IRI. The endogenous Gal-9 in the liver works as a protective factor and plays a crucial role in the maintenance of liver homeostasis. Administration of exogenous Gal-9, such as stable reGal-9, decreases liver damage due to IR. This study suggests a previously unrecognized function of Gal-9 and a new therapeutic strategy for liver IRI.

REFERENCES

1. Kishore U, Eggleton P, Reid KB. Modular organization of carbohydrate recognition domains in animal lectins. Matrix Biol 1997;15:583-592.
2. Rabbinovich GA, Toscano MA. Turning ‘sweet’ on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009;9:338-352.
3. van Kooyk Y, Rabbinovich GA. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol 2008;9:593-601.
4. Wada J, Kanwar YS. Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem 1997;272:6078-6086.
5. Wada J, Ota K, Kumar A, Wallner EI, Kanwar YS. Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. J Clin Invest 1997;99:2452-2461.
6. Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, et al. Human eacleactin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem 1998;273:16976-16984.
7. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005;6:1245-1252.
8. Seki M, Omizu S, Sakata KM, Sakata A, Arikawa T, Watanabe K, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol 2008;127:78-88.
9. Lv K, Xu W, Wang C, Niki T, Hirashima M, Xiong S. Galectin-9 administration ameliorates CVB3 induced myocarditis by promoting the proliferation of regulatory T cells and alternatively activated TH2 cells. Clin Immunol 2011;140:92-101.
10. Kadokawa T, Morishita A, Niki T, Hara J, Sato M, Tani J, et al. Galectin-9 prolongs the survival of septic mice by expanding Tim-3-expressing natural killer T cells and PDCA-1+ CD11c+ macrophages. Crit Care 2013;17:R284.
11. Crick FC, Shihe SJ, Sjytuw HK. Attenuation of Th1 response through galectin-9 and T-cell Ig mucin 3 interaction inhibits autoimmune diabetes in NOD mice. Eur J Immunol 2009;39:2403-2411.
12. Kanaki M, Wada J, Sugiyama K, Nakatsuka A, Teshigawara S, Murakami K, et al. Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes. Endocrinology 2012;153:612-620.
13. Mengshol JA, Golden-Mason L, Arkawa T, Smith M, Niki T, McWilliams R, et al. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One 2010;5:e9504.
14. Lv K, Zhang X, Zhang M, Zhong M, Suo Q. Galectin-9 ameliorates Con A-induced hepatitis by inducing CD4+ /CD25(low/int) effector T-cell apoptosis and increasing regulatory T cell number. PLoS One 2012;7:e48379.
15. Farmer DG, Amersi F, Kupecz-Weglinski J, Busuttil RW. Current status of ischemia and reperfusion injury in the liver. Transplant Rev 2000;14:106-126.
16. Teoh NC, Farrell GC. Hepatic ischemia reperfusion injury: pathogenic mechanisms and basis for hepatoprotection. J Gastroenterol Hepatol 2003;18:891-902.
17. Jaeschke H, Bautista AP, Spolarics Z, Spitzer JJ. Superoxide generation by Kupffer cells and priming of neutrophils during reperfusion after hepatic ischemia. Free Radic Res Commun 1991;15:277-284.
18. Hernandez LA, Grisham MB, Twohig B, Arfors KE, Harlan JM, Granger DN. Role of neutrophils in ischemia-reperfusion-induced microvascular injury. Am J Physiol 1987;253(part 2):H699-H703.
19. Zwacka RM, Zhang Y, Hallidtson J, Schlossberg H, Dudus L, Engelhardt JP. CD4+ T-lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver. J Clin Invest 1997;100:279-289.
20. Shen X, Wang X, Gao F, Ren F, Busuttil RW, Kupecz-Weglinski JW, Zhai Y. CD4 T cells promote tissue inflammation via CD40 signaling without de novo activation in a murine model of liver ischemia/reperfusion injury. Hepatology 2009;50:1537-1546.
21. Hanschen M, Zabler S, Krombach F, Khandoga A. Reciprocal activation between CD4+ T cells and Kupffer cells during hepatic ischemia-reperfusion. Transplantation 2008;86:710-718.
22. Khademi M, Illés Z, Gienal AW, Marta M, Takazawa N, Baecher-Allan C, et al. T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol 2004;172:7169-7176.
23. Wang X, He W, Yuan J, Wu K, Zhou H, Zhang W, Chen ZK. Activation of Tim-3-Galectin-9 pathway improves survival of fully allogeneic skin grafts. Transpl Immunol 2008;15:12-19.
24. Uchida Y, Ke B, Freitas MC, Ji H, Zhao D, Benjamin ER, et al. The emerging role of T cell immunoglobulin mucin-1 in the mechanism of liver ischemia and reperfusion injury in the mouse. Hepatology 2010;51:1363-1372.
25. Uchida Y, Ke B, Freitas MC, Yagita H, Akiba H, Busuttil RW, et al. T-cell immunoglobulin mucin-3 determines severity of liver ischemia/reperfusion injury in mice in a TLR4-dependent manner. Gastroenterology 2010;139:2195-2206.
26. Uchida Y, Freitas MC, Zhao D, Busuttil RW, Kupecz-Weglinski JW. The inhibition of neutrophil elastase...
ameliorates mouse liver damage due to ischemia and reperfusion. Liver Transpl 2009;15:939-947.

27. Nishi N, Itoh A, Fujiyama A, Yoshida N, Araya S, Hirashima M, et al. Development of highly stable galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett 2005;579:2058-2064.

28. Suzuki S, Toledo-Pereyra LH, Rodriguez FJ, Cevallo D. Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. Transplantation 1993;55:1265-1272.

29. Seki M, Sakata KM, Oomizu S, Arikawa T, Sakata A, Ueno M, et al. Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts. Arthritis Rheum 2007;56:3968-3976.

30. Lentsch AB, Yoshidome H, Cheadle WG, Miller FN, Edwards MJ. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and KC. Hepatology 1998;27:1172-1177.

31. Tsung A, Hoffman RA, Izuishi K, Critchlow ND, Nakao A, Chan MH, et al. Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol 2005;175:7661-7668.

32. Colletti LM, Remick DG, Burch GD, Kunkel SL, Strieter RM, Campbell DA Jr. Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 1990;85:1936-1943.

33. Lentsch AB, Kato A, Yoshidome H, McMasters KM, Edwards MJ. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. Hepatology 2000;32:169-173.

34. Uchida Y, Freitas MC, Zhao D, Busuttil RW, Kupiec-Weglinski JW. The protective function of neutrophil elastase inhibitor in liver ischemia/reperfusion injury. Transplantation 2010;89:1050-1056.

35. Rüdiger HA, Graf R, Clavien PA. Liver ischemia: apoptosis as a central mechanism of injury. J Invest Surg 2003;16:149-159.

36. Liu Y, Ji H, Zhang Y, Shen X, Gao F, He X, et al. Recipient T cell TIM-3 and hepatocyte galectin-9 signalling protects mouse liver transplants against ischemia-reperfusion injury. J Hepatol 2015;62:563-572.

37. Gooden MJ, Wiersma VR, Samplonius DF, Gerssen J, van Ginkel RJ, Nijman HW, et al. Galectin-9 activates and expands human T-helper 1 cells. PLoS One 2013;8:e65616.

38. Zhai Y, Shen XD, O'Connell R, Gao F, Lassman C, Busuttil RW, et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol 2004;173:7115-7119.

39. Nace GW, Huang H, Khune JR, Eid RE, Rosborough BR, Korff S, et al. Cellular-specific role of toll-like receptor 4 in hepatic ischemia-reperfusion injury in mice. Hepatology 2013;58:374-387.